Novartis Gilenya Approved With Advisory Panel-Enhanced REMS
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA follows the advice of its Peripheral and Central Nervous System Drugs Advisory Committee to ask doctors to do a range of testing and monitoring when they prescribe the MS drug.